SciClone Licenses New Ondansetron Forumulation From APR For Chinese, Vietnam Markets

SHANGHAI - California-based SciClone Pharmaceuticals inked an agreement with Switzerland-based Applied Pharma Research to license Ondansetron Rapidflim for China and Vietnam. Under the agreement, SciClone will pay APR $1 million plus milestone payments for marketing rights for 10 years following regulatory approval, according to SciClone